The Pathogenesis and Treatment Methods for Rett Syndrome
DOI:
https://doi.org/10.61173/tgn6qc18Keywords:
Rett Syndrome, MeCP2, DAYBUEAbstract
Rett Syndrome is a neurological condition primarily affecting women. Its symptoms include decreased brain size, inability to speak, and coordination problems. Several gene mutations have been discovered to play a role in this disease, with the MeCP2 mutation being the most widely known and frequent cause. Scientists are also attempting to create medicines targeting the genetic mutations that may provide a cure. However, the mechanism behind how MeCP2 affects the human brain on a molecular level remains to be discovered. This article summarises the important findings regarding the causes and the treatments of Rett Syndrome. It compares the current methods to treat this disease, including DAYBUE, the newly FDA-approved medicine and the only current medicine that targets Rett Syndrome. Future studies could revolve around the root causes of Rett Syndrome, such as the lack of MeCP2 in neurons, and attempt to solve the problem fundamentally. The findings are significant for humans to advance on finding a cure for this neurological disease.
References
[1] Buchanan C B, Stallworth J L, Joy A E, et al. Anxiety-like behavior and anxiolytic treatment in the Rett syndrome natural history study. Journal of Neurodevelopmental Disorders, 2022, 14(1): 31.
[2] May D, Kponee-Shovein K, Mahendran M, et al. The epidemiology and patient journey of Rett syndrome in the United States is a real-world evidence study. BMC Neurology 2023; 23(1).
[3] Smeets E E. Rett syndrome. Cassidy and Allanson’s Management of Genetic Syndromes, 2021: 791-806.
[4] Lopes AG, Loganathan SK, Caliaperumal J. Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials. Brain Sciences. 2024 Jan 24;14(2):120.
[5] Bienvenu, T.; Carrié, A.; de Roux, N.; Vinet, M.C., et al. MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum. Mol. Genet. 2000, 9, 1377-1384.
[6] Krishnaraj, R.; Ho, G.; Christodoulou, J. RettBASE: Rett syndrome database update. Hum. Mutat. 2017, 38, 922–931.
[7] Osman S, Yasui DH. The Molecular Functions of MECP2 in Rett Syndrome Pathology. Frontiers in Genetics. 2021 Apr 23;12.
[8] Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rettlike phenotype in mice. Nature Genetics. 2001 Mar 1;27(3):327– 31.
[9] MECP2 gene: MedlinePlus Genetics. Available from: https:// medlineplus.gov/genetics/gene/mecp2/
[10] Na ES, Nelson ED, Kavalali ET, Monteggia LM. The Impact of MeCP2 Loss- or Gain-of-Function on Synaptic Plasticity. Neuropsychopharmacology. 2012 Jul 11;38(1):212–9.
[11] Neul, J.L.; Fang, P.; Barrish, J.; Lane, J., et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008, 70, 1313–1321
[12] Kruusvee, V.; Lyst, M.J.; Taylor, C.; Tarnauskaitė, Ž.; Bird, A.P.; Cook, A.G. Structure of the MeCP2-TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders. Proc. Natl. Acad. Sci. USA 2017, 114, E3243-E3250.
[13] Malcolm E. Atypical Rett Syndrome–Rett Syndrome News. Rett Syndrome News. 2019. Available from: https:// rettsyndromenews.com/atypical-rett-syndrome/.
[14] Cordeiro M. A first for Rett: FDA approves trofinetide for treatment of Rett syndrome! - International Rett Syndrome Foundation. International Rett Syndrome Foundation. 2023. Available from: https://www.rettsyndrome.org/ trofinetideapproved/.
[15] GoodRx - Error. Available from: www.goodrx.com/daybue/ what-is.
[16] Bryn Mawr Communications. Full Results from LAVENDER Study Confirm Benefits of Daybue to Treat Rett Syndrome Symptoms - Practical Neurology. Available from: https://practicalneurology.com/news/full-results-from-lavenderstudy- confirm-benefits-of-daybue-to-treat-rett-syndromesymptoms.
[17] Coenraads, Monica. “DAYBUE (Trofinetide): Key Facts for Parents.” Rett Syndrome Research Trust, 20 Apr. 2023, reverserett.org/news/articles/daybue-trofinetide-key-facts-forparents.
[18] Kennedy M, Neul J L, Tropea D, et al. Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. Frontiers in Pharmacology, 2024, 14: 1341746.
[19] Przanowski P, Wasko UN, Zheng Z, et al. Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice. Proceedings of the National Academy of Sciences of the United States of America. 2018 Jul 16;115(31):7991–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
